CRISPR Therapeutics (CRSP) Tops Q1 EPS by 107c

CRISPR Therapeutics (NASDAQ: CRSP) reported Q1 EPS of ($0.67), $1.07 better than the analyst estimate of ($1.74). Revenue for the quarter came in at $100 million versus the consensus estimate of $25.85 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Creatd files Form S-1 and reports Q1 2026 financial results
• BofA lists top 5 themes driving next $1tn in incremental semi sales